About Us

R&D Pipeline

We are focused on topical bacterial infection since the size of the market is so large and there are virtually no totally effective and affordable solutions. Over time, we will look to in-license other later stage biological dermatological treatments.

Management Team

Mark Engel

CEO

Previously founded 4 successful life sciences companies

Dr. Nancy Tawil 

Chief Scientific Officer

Ph.D in Biomedical Engineering and Phage Expert



Dr. Assaf Raz

Vice President of R & D in China &

Director of Wuhan Laboratory

Ph.D in Biology, Rockefeller University and Leading Global Lysin Expert

Sandy Li

Quality Manager

M.S. in Chemistry. Experienced in GMP

drug production



Dr. Mya Thandar

Chief Research Scientist

Ph.D in Biology and years of experience in the development of phage lysins


Overview

Phagelux is a Cayman platform company that utilizes phages and novel delivery systems to create First in Class treatments for large unmet or under met skin conditions. Phagelux Targets are effectively preventing and treating AMR resistant topical infections. Phagelux subsidiary Lysigen utilizes lysins to create first or best-in-class antibacterials with a focus on skin diseases. Phagelux has an R&D center in Montreal, Canada focused on bacteriophage products. Lysigen is located in Wuhan China and focuses on lysin products.

Phagelux has significant IP and unique knowhow. In total, 28 patents have been filed in China, US, Europe, and other key markets, and 8 patents have been issued. These include patents of preparation method and method of use. In addition, Phagelux has unique platform knowhow in phage delivery and Lysigen has a fast high throughput lysin development system.

Phagelux has two products ready to start clinical trials.






技术支持: 赛泊斯 | 管理登录